German biotech company BioNTech – which has become world famous for its corona vaccine – has started testing a malaria vaccine.
The company announced it on Friday.
The first patient received a first dose of the vaccine on December 21. The phase 1 trial of the BNT165b1 vaccine candidate will be tested on 60 people. The goal is to develop a vaccine that can help prevent malaria and reduce mortality, says co-founder Özlem Türeci.
In 2021 alone, 619,000 people died from malaria, many of them young children in Africa. BioNTech isn’t the only company working on a malaria vaccine. Moderna has also announced that it is looking for a vaccine, as has the University of Oxford. GSK has already developed a vaccine that provides 40% protection.
The BioNTech post-test malaria vaccine appeared first on Knack.
